Zobrazeno 1 - 10
of 14
pro vyhledávání: '"J C, Niland"'
Autor:
H J, Kissler, J C, Niland, B, Olack, C, Ricordi, B J, Hering, A, Naji, F, Kandeel, J, Oberholzer, L, Fernandez, J, Contreras, T, Stiller, J, Sowinski, D B, Kaufman
Publikováno v:
Clinical transplantation. 24(2)
Quantification of islet mass is a crucial criterion for defining the quality of the islet product ensuring a potent islet transplant when used as a therapeutic intervention for select patients with type I diabetes.This multi-center study involved all
Autor:
J C, Niland
Publikováno v:
Oncology (Williston Park, N.Y.). 14(11A)
Since 1997, the National Comprehensive Cancer Network (NCCN) outcomes database has successfully collected and reported patterns of care and outcomes data in the oncology setting. Breast cancer was the first cancer site chosen for this outcomes study,
Autor:
A, Krishnan, S, Bhatia, M L, Slovak, D A, Arber, J C, Niland, A, Nademanee, H, Fung, R, Bhatia, A, Kashyap, A, Molina, M R, O'Donnell, P A, Parker, I, Sniecinski, D S, Snyder, R, Spielberger, A, Stein, S J, Forman
Publikováno v:
Blood. 95(5)
We analyzed data on 612 patients who had undergone high-dose chemoradiotherapy (HDT) with autologous stem cell rescue for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the City of Hope National Medical Center, to evaluate the incidence o
Autor:
J C, Niland
Publikováno v:
Oncology (Williston Park, N.Y.). 12(11A)
The National Comprehensive Cancer Network (NCCN), an alliance of 17 of the world's leading cancer centers, is currently conducting its first shared outcomes project in breast cancer. City of Hope National Medical Center serves as the data coordinatin
Autor:
N J, Chao, P M, Parker, J C, Niland, R M, Wong, A, Dagis, G D, Long, A P, Nademanee, R S, Negrin, D S, Snyder, W W, Hu, K A, Gould, D K, Tierney, K, Zwingenberger, S J, Forman, K G, Blume
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2(2)
Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs.-host disease (GVHD). To determine its efficacy as a prophylactic agent for the prevention of chronic GVHD, a prospective randomized double-blind study was p
Autor:
J A, Zaia, G M, Schmidt, N J, Chao, N W, Rizk, A P, Nademanee, J C, Niland, D A, Horak, J, Lee, G, Gallez-Hawkins, C R, Kusnierz-Glaz
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 1(2)
The use of ganciclovir at the time of cytomegalovirus (CMV) infection but before disease onset has been termed "preemptive" therapy. This preemptive ganciclovir administration has been shown to be an effective method for preventing severe CMV disease
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 1(1)
To assess the statistical methods in the bone marrow transplantation (BMT) literature, we reviewed 255 articles from eight major journals (Annals of Internal Medicine, Blood, British Journal of Cancer, Cancer, Lancet, Journal of Clinical Oncology, Ne
Autor:
P M, Parker, N, Chao, A, Nademanee, M R, O'Donnell, G M, Schmidt, D S, Snyder, A S, Stein, E P, Smith, A, Molina, D E, Stepan, A, Kashyap, I, Planas, R, Spielberger, G, Somlo, K, Margolin, K, Zwingenberger, K, Wilsman, R S, Negrin, G D, Long, J C, Niland, K G, Blume, S J, Forman
Publikováno v:
Blood. 86(9)
Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (P
Autor:
P. Khrizman, J. C. Niland, A. ter Veer, D. Milne, K. Bullard Dunn, W. E. Carson, P. F. Engstrom, S. Shibata, J. M. Skibber, M. R. Weiser, D. Schrag, A. B. Benson
Publikováno v:
Journal of Clinical Oncology. 29:3515-3515
Publikováno v:
The New England journal of medicine. 324(15)
Cytomegalovirus (CMV)-associated interstitial pneumonia is a major cause of death after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir in recipients of bone marrow transplants who had asymptomatic pulmonary CMV